Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ELOVL fatty acid elongase 1 (ELOVL1) is a membrane-bound enzyme located in the endoplasmic reticulum that catalyzes the first and rate-limiting step of the fatty acid elongation cycle, specifically facilitating the addition of two carbon units to long-chain and very long-chain saturated and monounsaturated fatty acyl-CoA substrates via a condensation reaction with malonyl-CoA[1][2][3]. ELOVL1 is fundamental for the biosynthesis of very long chain fatty acids (VLCFAs), which are essential precursors for membrane lipids and sphingolipids critical for myelin sheath integrity, skin barrier function, and other biological roles[1][2][3]. Mutations in ELOVL1 are associated with rare neurological and dermatological syndromes involving hypomyelination, ichthyosis, and spasticity, indicating its vital importance in human physiology[1][2].
Inhibition of fatty acid chain elongation (for enzyme inhibitors, experimental)[3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ELOVL fatty acid elongase 1 (ELOVL1).